IL17A and psoriasis: KCASP1Tg+IL-17AFKO mice demonstrated an increased proportion of Type 2 cells compared to WT mice in the lesional skin, aligning with clinical observations that IL-17 blockade in psoriasis patients shifts the cytokine environment from a psoriasis-like inflammatory profile to one more characteristic of AD [59,60].